{"nctId":"NCT00046930","briefTitle":"Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia","startDateStruct":{"date":"2002-09-17","type":"ACTUAL"},"conditions":["Leukemia","Myelodysplastic Syndromes"],"count":449,"armGroups":[{"label":"Zosuquidar","type":"EXPERIMENTAL","interventionNames":["Biological: filgrastim","Biological: sargramostim","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: zosuquidar trihydrochloride"]},{"label":"Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: filgrastim","Biological: sargramostim","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: Placebo"]}],"interventions":[{"name":"filgrastim","otherNames":["Neupogen, recombinant-methionyl human granulocyte-colony stimulating factor,","granulocyte colony-stimulating factor, r-metHuG-CSF"]},{"name":"sargramostim","otherNames":["Granulocyte-macrophage colony stimulating factor, rHu GM-CSF,","Leukine, NSC # 617589"]},{"name":"cytarabine","otherNames":["Cytosar-U, Ara-C, Arabinosyl, cytosine arabinoside."]},{"name":"daunorubicin hydrochloride","otherNames":["Daunomycin, Rubidomycin, Cerubidine."]},{"name":"zosuquidar trihydrochloride","otherNames":["Multi drug resistance modulator, MDR, LY335979"]},{"name":"Placebo","otherNames":["Baxter Infuvite Adult"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nOne of the following disorders:\n\n* Acute myeloid leukemia (AML), defined as \\>30% myeloblasts on the marrow aspirate or peripheral blood differential and any French-American-British (FAB) subtype except M3 (i.e., acute promyelocytic leukemia)\n* Refractory anemia with excess blasts (RAEB), defined as 11-20% myeloblasts on bone marrow aspirate or peripheral blood differential, provided there are other criteria for high-risk disease\n* Refractory anemia with excess blasts in transformation (RAEB-T), defined as 21-30% myeloblasts on bone marrow aspirate or peripheral blood differential\n* Participants may have secondary AML\n* Age greater than 60 years\n* ECOG performance status of 0 to 3\n* Total serum bilirubin \\< 3 mg/dL\n* Serum creatinine \\< 2 mg/dL\n* Cardiac ejection fraction of \\> 45%\n\nExclusion Criteria:\n\n* Blastic transformation of chronic myelogenous leukemia\n* CNS leukemia\n* Prior chemotherapy for AML, with the exception of hydroxyurea\n* For women: pregnant or breast feeding\n* Other malignancy for which participant is currently receiving treatment\n* Concurrent treatment with other colony-stimulating factors","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Time from randomization to death. Patients alive at last follow-up were censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.23","spread":null},{"groupId":"OG001","value":"9.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Time from randomization to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":null},{"groupId":"OG001","value":"2.04","spread":null}]}]}]},{"type":"SECONDARY","title":"Response","description":"Number of eligible participants in each response category. Categories, based on peripheral blood counts and bone marrow aspirate and biopsy, include complete remission (CR), partial remission (PR), morphologic complete remission (MCR), and relapse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":216,"n":219},"commonTop":["Anemia","Thrombocytopenia","Leukopenia","Neutropenia","Bilirubin Increased"]}}}